Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25(2):74–85. doi:10.1016/j.suronc.2016.03.00227312032
   PubMed Web of Science ®Google Scholar
• Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342(6248):440–443. doi:10.1038/342440a02531289
   PubMed Web of Science ®Google Scholar
• Lokker NA, Mark MR, Luis EA, et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 1992;11(7):2503–2510. doi:10.1002/embj.1992.11.issue-71321034
   PubMed Web of Science ®Google Scholar
• Naka D, Ishii T, Yoshiyama Y, et al. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J Biol Chem. 1992;267(28):20114–20119.1328193
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12(12):3657–3660. doi:10.1158/1078-0432.CCR-06-081816778093
   PubMed Web of Science ®Google Scholar
• Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K. Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer. 2007;121(2):276–283. doi:10.1002/(ISSN)1097-021517372907
   PubMed Web of Science ®Google Scholar
• Hara S, Nakashiro K, Klosek SK, Ishikawa T, Shintani S, Hamakawa H. Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncol. 2006;42(6):593–598. doi:10.1016/j.oraloncology.2005.10.01616469527
   PubMed Web of Science ®Google Scholar
• Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25(3):619–623. doi:10.1002/(ISSN)1527-33509049208
   PubMed Web of Science ®Google Scholar
• Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer. 2010;46(7):1260–1270. doi:10.1016/j.ejca.2010.02.02820303741
   PubMed Web of Science ®Google Scholar
• Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67(3):1132–1149. doi:10.1002/hep.v67.328862760
   PubMed Web of Science ®Google Scholar
• Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011;11(12):1655–1662. doi:10.1517/14712598.2011.62676222047509
   PubMed Web of Science ®Google Scholar
• Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111(Pt 2):237–247.9405310
   PubMed Web of Science ®Google Scholar
• Ohashi K, Marion PL, Nakai H, et al. Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med. 2000;6(3):327–331. doi:10.1038/7318710700236
   PubMed Web of Science ®Google Scholar
• Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20 Pt 1):6144–6152. doi:10.1158/1078-0432.CCR-05-141817062691
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008;68(11):4360–4368. doi:10.1158/0008-5472.CAN-07-596018519697
   PubMed Web of Science ®Google Scholar
• Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013;110(32):E2987–E2996. doi:10.1073/pnas.130272511023882082
   PubMed Web of Science ®Google Scholar
• Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006;66(3):1721–1729. doi:10.1158/0008-5472.CAN-05-332916452232
   PubMed Web of Science ®Google Scholar
• van der Horst EH, Chinn L, Wang M, et al. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 2009;11(4):355–364. doi:10.1593/neo.8153619308290
   PubMed Web of Science ®Google Scholar
• Liu L, Zeng W, Wortinger MA, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014;20(23):6059–6070. doi:10.1158/1078-0432.CCR-14-054325231402
   PubMed Web of Science ®Google Scholar
• Tao J, Xiang JJ, Li D, Deng N, Wang H, Gong YP. Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. Biochem Biophys Res Commun. 2010;394(3):767–773. doi:10.1016/j.bbrc.2010.03.06720227391
   PubMed Web of Science ®Google Scholar
• Liu Z, Feng Z, Zhu X, et al. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL. Immunol Lett. 2013;149(1–2):30–40. doi:10.1016/j.imlet.2012.09.00623026237
   PubMed Web of Science ®Google Scholar
• Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011;32(12):3265–3274. doi:10.1016/j.biomaterials.2010.12.06121306768
   PubMed Web of Science ®Google Scholar
• Qamsari ES, Sharifzadeh Z, Bagheri S, et al. Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies. J Immunotoxicol. 2017;14(1):23–30. doi:10.1080/1547691X.2016.125151228090795
   PubMed Web of Science ®Google Scholar
• Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 2006;147(5):2557–2566. doi:10.1210/en.2005-140416469801
   PubMed Web of Science ®Google Scholar